ID   Hep-KANO clone 2
AC   CVCL_Y144
SY   Hep-KANO CL-2; Hep-KANO CL2
DR   CGH-DB; 9077-4
DR   Wikidata; Q54882795
RX   PubMed=7829395;
RX   PubMed=12029633;
CC   Population: Japanese.
CC   Doubling time: 36 hours (PubMed=7829395).
CC   Transformant: NCBI_TaxID; 10407; Hepatitis B virus (HBV).
DI   NCIt; C7956; Adult hepatocellular carcinoma
DI   ORDO; Orphanet_210159; Adult hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_Y143 ! Hep-KANO clone 1
SX   Male
AG   42Y
CA   Cancer cell line
DT   Created: 07-11-14; Last updated: 21-03-23; Version: 6
//
RX   PubMed=7829395; DOI=10.1111/j.1349-7006.1994.tb02914.x; PMCID=PMC5919368;
RA   Baba, Masaru
RA   Hasegawa, Hiroshi
RA   Nakayabu, Masahiro
RA   Tamaki, Shigenori
RA   Watanabe, Shozo
RA   Shima, Teruo
RA   Suzuki, Shiro
RA   Kusano, Itsuo
RA   Kamada, Nanao
RT   "Characteristics of human hepatocellular carcinoma cell lines
RT   (Hep-KANO) derived from a non-hepatitic, non-cirrhotic hepatitis B
RT   virus carrier.";
RL   Jpn. J. Cancer Res. 85:1105-1111(1994).
//
RX   PubMed=12029633; DOI=10.1053/jhep.2002.33683;
RA   Yasui, Kohichiroh
RA   Arii, Shigeki
RA   Zhao, Chen
RA   Imoto, Issei
RA   Ueda, Masakazu
RA   Nagai, Hisaki
RA   Emi, Mitsuru
RA   Inazawa, Johji
RT   "TFDP1, CUL4A, and CDC16 identified as targets for amplification at
RT   13q34 in hepatocellular carcinomas.";
RL   Hepatology 35:1476-1484(2002).
//